SCHEMBL30004264

SCHEMBL30004264

COC(=O)c1c(CBr)ccc(Br)c1OC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
MAPT P10636 3/20 0.40
USP2 O75604 1/20 0.40
ALOX15 P16050 1/20 0.40
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38
CA14 Q9ULX7 1/20 0.38
HTR1A P08908 1/20 0.36
ADRA2A P08913 1/20 0.36
CYP2D6 P10635 1/20 0.36
DRD2 P14416 1/20 0.36
ADRA2C P18825 1/20 0.36
DRD4 P21917 1/20 0.36
CYP2C19 P33261 1/20 0.36
ADRA1A P35348 1/20 0.36
DRD3 P35462 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL436677 1.00 MEN1 (0.40) MEN1KMT2AMAPTUSP2ALOX15
SCHEMBL27867882 0.88 MAPT (0.39) MEN1KMT2AMAPTUSP2ALOX15
SCHEMBL1648090 0.86 MAPT (0.55) MEN1KMT2AMAPTUSP2ALOX15
SCHEMBL31522081 0.86 MAPT (0.42) MEN1KMT2AMAPTUSP2ALOX15
SCHEMBL6844843 0.85 HSD17B10 (0.42) MEN1KMT2AMAPTUSP2ALOX15
SCHEMBL18801480 0.84 MEN1 (0.39) MEN1KMT2AMAPTUSP2ALOX15
SCHEMBL18801479 0.83 MEN1 (0.38) MEN1KMT2AMAPTUSP2ALOX15
SCHEMBL31522029 0.83 KDM4E (0.45) MEN1KMT2AMAPTCA12CA1
SCHEMBL1649000 0.82 CA12 (0.43) MEN1KMT2AMAPTUSP2ALOX15
SCHEMBL14725788 0.82 CA1 (0.38) MEN1KMT2AMAPTUSP2ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025043225-A2 DEGRADERS OF CYCLIN-DEPENDENT KINASE 2 GENENTECH, INC. (US) 2025-02-27 WO disclosed
EP-4323350-A1 ISOINDOLINONE COMPOUNDS Monte Rosa Therapeutics AG (CH) 2024-02-21 EP disclosed
WO-2023069720-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS, INC. (US) 2023-04-27 WO disclosed
WO-2022219407-A1 ISOINDOLINONE COMPOUNDS MONTE ROSA THERAPEUTICS AG (CH) 2022-10-20 WO disclosed